In patients with SEA, continued reductions in clinically significant exacerbations were reported with mepolizumab administration after 2 years of follow-up.
After 24 weeks, the use of icenticaftor on top of triple inhalation therapy resulted in a clear dose-response on 5 endpoints in patients with COPD and chronic bronchitis.
A pharmacy-supported digital programme improved therapy and technique adherence for uncontrolled asthma patients, leading to better asthma control.
Point-of-care eosinophil-guided prednisolone was non-inferior to its standard-of-care prescription in treating COPD exacerbations, a trial showed.
Cardiology moves between life and death. The extent to which artificial intelligence could help or replace doctors in this field is a subject of passionate debate.
According to a study, smokers suffer from heart failure more frequently than non-smokers of the same age. The underlying changes in the heart are visible.
A trial demonstrated a doubling of PFS and a near doubling of overall survival with the VEGF-1, -2, and -3 inhibitor in patients with refractory mCRC.
Echocardiography to assess aortic stenosis severity, supported by a novel AI algorithm, can better identify patients at high death risk who could benefit from treatment.
An invasive ischaemia treatment in CKD and chronic coronary disease patients was not superior to conservative management for deaths reduction after 5 years.
A meta-analysis in Marfan syndrome patients concluded that both drugs have similar, substantial, and independent effects on reducing aortic root size.
The trial showed that dose response was not observed, yet a 30% relative risk reduction was seen in symptomatic ischaemic strokes with milvexian.
In rheumatic heart disease-associated AF patients, VKAs therapy was non-inferior to rivaroxaban for a composite of cardiovascular events or death rates.
Multisystemic inflammatory syndrome can appear in children and adolescents as a consequence of SARS-CoV-2 infection.
Surgery planning, education or even communication: Virtual and augmented reality give room to many applications in patient-physician interactions.
A prospective study showed that the medication did not reduce events, including non-fatal MI, non-fatal stroke, or cardiovascular death, in patients with IHD.
Treating severe hypertriglyceridaemia patients with subcutaneous pegozafermin significantly reduced triglycerides across all study dose groups.
SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisation for heart failure across HFpEF/HFmrEF patient subgroups.
In severe ischaemic left ventricular systolic dysfunction patients, PCI did not reduce the composite incidence of all cause death or hospitalisation for heart failure.
The BOX trial shows that outcomes of comatose patients after an OHCA are not affected by shifting targets of oxygenation or blood-pressure.
A high-dose vaccination (60 μg of haemagglutinin antigen) in older adults reduced death risk by 49% and hospitalisation by 64%, compared with standard-dose vaccination.